Fengshuo Lan
Hematology & Oncology · Stony Brook, NYNPI 1649337122
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,621 of the $29,396 with a category attached, or 80.4%. AstraZeneca accounts for 87.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $19,073 and has fallen 99.4% since, to $111 in 2024.
Across 45 payments — averaging $653.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$26K
- Kyowa Kirin, Inc.$4K
- Regeneron$56
- Sobi, Inc$54
Across 15 payments — averaging $54,491 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$631K
- Pharmaessentia USA Corporation$186K
What the payments were for
- Consulting fees$3501%
- Speaking & faculty fees$23,62180%
- Travel & lodging$4,26715%
- Food & beverage$1,1594%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $25,736 |
| Kyowa Kirin, Inc. | 1 | $3,550 |
| Regeneron | 1 | $56 |
| Sobi, Inc | 2 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,396 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 16 | $310,380 |
| ThalomidThalidomide | 14 | $249,397 |
| ImbruvicaIbrutinib | 15 | $226,320 |
| PrevymisLetermovir | 15 | $118,700 |
| EliquisApixaban | 60 | $62,514 |
| Voriconazole | 18 | $11,814 |
| Cyclosporine | 17 | $4,829 |
| Entecavir | 12 | $3,857 |
| Enoxaparin Sodium | 19 | $3,672 |
| ValacyclovirValacyclovir Hcl | 23 | $950 |
| Hydroxyurea | 34 | $864 |
| Ursodiol | 22 | $790 |
| Acyclovir | 28 | $276 |
| Oxycodone Hcl | 14 | $199 |
| Levothyroxine Sodium | 17 | $155 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stony Brook
- Jules CohenStony Brook$557K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.